- Home
- TEI vs MREO Comparison
TEI vs MREO Comparison
Compare TEI & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- MREO
- Stock Information
- Founded
- TEI 1993
- MREO 2015
- Country
- TEI United States
- MREO United Kingdom
- Employees
- TEI N/A
- MREO N/A
- Industry
- TEI Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- MREO Health Care
- Exchange
- TEI Nasdaq
- MREO Nasdaq
- Market Cap
- TEI 282.9M
- MREO 286.4M
- IPO Year
- TEI N/A
- MREO N/A
- Fundamental
- Price
- TEI $6.28
- MREO $1.79
- Analyst Decision
- TEI
- MREO Strong Buy
- Analyst Count
- TEI 0
- MREO 5
- Target Price
- TEI N/A
- MREO $7.40
- AVG Volume (30 Days)
- TEI 142.4K
- MREO 1.5M
- Earning Date
- TEI 01-01-0001
- MREO 11-10-2025
- Dividend Yield
- TEI 10.51%
- MREO N/A
- EPS Growth
- TEI N/A
- MREO N/A
- EPS
- TEI N/A
- MREO N/A
- Revenue
- TEI N/A
- MREO $500,000.00
- Revenue This Year
- TEI N/A
- MREO N/A
- Revenue Next Year
- TEI N/A
- MREO $72.16
- P/E Ratio
- TEI N/A
- MREO N/A
- Revenue Growth
- TEI N/A
- MREO N/A
- 52 Week Low
- TEI $4.35
- MREO $1.47
- 52 Week High
- TEI $5.39
- MREO $3.94
- Technical
- Relative Strength Index (RSI)
- TEI 44.27
- MREO 43.68
- Support Level
- TEI $6.27
- MREO $1.75
- Resistance Level
- TEI $6.50
- MREO $1.90
- Average True Range (ATR)
- TEI 0.08
- MREO 0.10
- MACD
- TEI -0.02
- MREO -0.00
- Stochastic Oscillator
- TEI 5.98
- MREO 50.00
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).